An Omics-Based Screening Tool to Determine the Risk of Developing Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) has a variable penetrance of 50%. Half of all patients who are diagnosed with HCM will fail to develop a HCM phenotype throughout their lives. Omics is a useful tool for developing a diagnostics model for HCM and could enable the identification of patients who will develop HCM later in life.

Source: Heart, Lung and Circulation - July 1, 2023 Category: Cardiology Authors: D. Reinke, E. Kristianto, M. Alsherbiny, L. Hool Source Type: research